Activist Starboard Value did not nominate any directors to Pfizer’s (PFE) board ahead of a January 25 deadline for the company’s annual meeting in April, Damian Garde and Crystal Tse of Bloomberg report, citing people familiar with the matter. The news removes some of the pressure on Pfizer CEO Albert Bourla, but Starboard, which took a $1B stake in the company late last year, could still propose changes to the board in 2026 if the two sides don’t reach a settlement before then, Bloomberg says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer (PFE) Pays $59.7 Million Fine to Resolve Charges in Kickback Scheme
- Pfizer to pay ~$60M to settle Medicare false claims
- Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies
- Morgan Stanley Backs Chipmaker Qorvo after Starboard Stake
- Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards